| |
Resume| AREAS OF EXPERTISE | |
|---|---|
| Strategic in-and out-licensing and partnering | Leading cross-functional due diligence teams |
| Corporate Mergers and Acquisitions (M&A) | C-suite and Board of Directors presentations |
| Deal sourcing, structuring, negotiation, and execution | Rare disease and specialty pharma |
| IN BRIEF |
|---|
| A strategic life sciences business development executive with a keen ability to craft innovative solutions in uncharted territory that optimize enterprise value and propel success. End-to-end deal leadership across in/out licensing, M&A, divestitures, and strategic partnerships representing companies of all sizes. |
| SELECTED ACCOMPLISHMENTS |
|---|
| Sourced and advanced an under-indexed exit enabling, de-risked, near-term accretive asset expected to become Standard-of-Care; Product is positioned to materially grow sales and extend company IP runway by 6+ years. |
| Sourced and negotiated favorable partnering terms for a de-risked Phase III asset which became the company's lead product. Drug was successfully launched four years later. |
| Architected a growth strategy and a new life sciences service for a healthcare informatics company by re-using medical records to identify rare disease patients earlier and connect them with relevant clinical trials. New service supported a 35% valuation uplift and a $275 million acquisition by a PE firm. |
| Structured, negotiated, and aligned parties on a development and commercialization agreement with a Japanese partner for a new rare disease indication; bridged divergent regulatory and commercial outlooks, resolved supply and cross-border challenges, and de-risked key uncertainties. Uplifted milestones 45% and added tiered double digit royalties with tail. |
| Built a pipeline of near-term accretive, synergistic follow-on opportunities that support growth optionality. |
| One of a three-person C-suite team presenting company to Wall Street, resulting in a $6 million private placement with a $2 million follow-on. |
| R&D portfolio management and optimization: Created an interactive, predictive valuation model that incorporated insights and consistently ranked drug targets to streamline project selection. Applied model to prioritize a portfolio of 300 pipeline projects. Results: Improved profitability, optimized R&D resources, and helped increase annual FDA submissions from 5 to 14. |
| Identified market opportunities, led processes, and secured commercial partners for pipeline assets. Negotiated licensing and partnering terms. Managed alliances. |
| Developed strategic portfolio valuations and business case that positioned a pharmaceutical company to secure a $10 million private placement and complete a successful spinout. |
| Led a Fortune 500 company through transition from earning-per-share growth targets to cash-based measures. Analyzed company's portfolio to optimize performance across seven business units. Mentored senior executives and trained analysts on Value Management. This increased business plan correlation with shareholder value creation by roughly 30%. |
| EXPERIENCE | |
|---|---|
| Paratek Pharmaceuticals, King of Prussia, PA A PE-backed commercial pharmaceutical company Vice President, Business Development | 2024 - Current |
| Intercept Pharmaceuticals, Morristown, NJ A public commercial biopharmaceutical company Global Head Business Development | 2021 - 2024 |
| Alyon Inc. Hackensack, NJ A US subsidiary of a Swiss pharmaceutical company Head of Business Development, North America | 2016 - 2021 |
| Luminant, LLC, Stamford, CT A life science business development consulting firm Senior Business Development and Strategy Consultant | 2008 - Current |
| EARLIER STRATEGY AND FINANCE EXPERIENCE |
|---|
| Innapharma, Inc., Suffern, NY A pharmaceutical company and a contract research organization (CRO) Acting CFO |
| Taro Pharmaceuticals, USA, Hawthorne, NY A public multinational pharmaceutical company Director, Financial Analysis and Strategic Planning |
| Public Service Electric and Gas (PSE&G), Newark, NJ A Fortune 500 electric and gas company Business Analysis Manager |
| EDUCATION |
|---|
| Master of Business Administration (MBA), Finance and International Business, Stern School of Business, New York University, New York, NY |
Bachelor of Science (B.Sc.), Cum Laude in Chemistry, The Hebrew University, Jerusalem, Israel
|
| HONORS |
|---|
| Management Honors Program, Weizmann Institute, Rehovot, Israel Selected from the top ten graduates of all universities. Awarded a scholarship for excellence. |